Kalaris Therapeutics, Inc. Common Stock
$3.23
Market Cap
$75.70M
Shares Outstanding
23.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Mar 19, 2025
Round Lot
100
Locale
US
Day Open
$3.20
Day High
$3.27
Day Low
$3.20
Volume
25.8K
VWAP
$3.23
Prev Close
$3.18
Transactions
--
Acc. Volume
--
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Kalaris Therapeutics, Inc. Common Stock (KLRS) closed the 2026-09-17 session at $3.23, up 1.57% versus the previous close (+0.05). The stock opened at $3.20 and traded between $3.20 and $3.27 during that session. Session trading volume was 26K shares. The volume-weighted average price (VWAP) is $3.23.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Kalaris Therapeutics, Inc. Common Stock has a market capitalization of $75.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. KLRS is listed on the XNAS exchange. The company employs approximately 20 people. Kalaris Therapeutics, Inc. Common Stock is headquartered in BERKELEY HEIGHTS, NJ. The recorded listing date is 2025-03-19.
On this page you can find market KLRS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.